Physician profile
Peter Dahl
NPI 1306001599
$617.67
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.78 | 2019 | |
| Novo Nordisk INC | $75.63 | 2019 | |
| Medtronic Minimed, INC. | $74.36 | 2019 | |
| Lilly USA, LLC | $64.11 | 2019 | |
| Radius Health, INC. | $61.43 | 2019 | |
| Merck Sharp & Dohme LLC | $41.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.29 | 2019 | |
| Amgen INC. | $19.57 | 2019 | |
| Ucb, INC. | $17.29 | 2019 | |
| Ibsa Pharma INC. | $16.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.05 | 2019 | |
| Shire North American Group INC | $12.50 | 2019 | |
| Abbott Laboratories | $11.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.